ToolGen, Inc. Announces Poster Presentation on Genome Editing of …EconoTimesEconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical …and more&n… Continue reading
CNA Finance |
Sangamo Therapeutics Presents Recent Developments from Research and Clinical Programs at Annual Meeting of the …
GuruFocus.com “Sangamo is known for its leading research in genome editing, and over time we have developed additional expertise in gene therapy, gene regulation and cell therapy. We are also rapidly advancing our viral and non-viral delivery capabilities which have … Sangamo BioSciences Inc. (SGMO) Moves Lower on Volume Spike for May 16Equities.com |
High Point Observer |
Sangamo Therapeutics Presents Recent Developments from Research and Clinical Programs at Annual Meeting of the …
PR Newswire (press release) “Sangamo is known for its leading research in genome editing, and over time we have developed additional expertise in gene therapy, gene regulation and cell therapy. We are also rapidly advancing our viral and non-viral delivery capabilities which have … Sangamo BioSciences Inc. (SGMO) Moves Lower on Volume Spike for May 16Equities.com |
|
Selecta Biosciences (SELB) Announces New Preclinical Gene Therapy Data at ASGCT
StreetInsider.com “Immunogenicity is a key challenge in gene therapy, limiting the number of diseases and patients that can be effectively treated and presenting a safety hurdle,” said Werner Cautreels, Ph.D., CEO and Chairman of Selecta. “Together with various … |
|
Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of …
GlobeNewswire (press release) “Immunogenicity is a key challenge in gene therapy, limiting the number of diseases and patients that can be effectively treated and presenting a safety hurdle,” said Werner Cautreels, Ph.D., CEO and Chairman of Selecta. “Together with various … |
|
Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of …
GlobeNewswire (press release) “Immunogenicity is a key challenge in gene therapy, limiting the number of diseases and patients that can be effectively treated and presenting a safety hurdle,” said Werner Cautreels, Ph.D., CEO and Chairman of Selecta. “Together with various … |